FOLH1 and Familial prostate cancer: Concurrent with the development of PSMA-targeted imaging, the application of PSMA-targeted radioligand therapy is an ongoing area of great potential, and several PSMA-targeted radiopharmaceuticals have been developed for the treatment of advanced prostate cancer which enable the delivery of radiation to both bone and soft tissue tumor sites.